JP7301540B2 - 抗体の混合物 - Google Patents

抗体の混合物 Download PDF

Info

Publication number
JP7301540B2
JP7301540B2 JP2018562201A JP2018562201A JP7301540B2 JP 7301540 B2 JP7301540 B2 JP 7301540B2 JP 2018562201 A JP2018562201 A JP 2018562201A JP 2018562201 A JP2018562201 A JP 2018562201A JP 7301540 B2 JP7301540 B2 JP 7301540B2
Authority
JP
Japan
Prior art keywords
antibody
human
binds
antibodies
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018562201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520063A5 (https=
JP2019520063A (ja
Inventor
ウェイ ヤン，
ジ リウ，
マーティン ジェイ． ペントニー，
Original Assignee
チールー ピュージェット サウンド バイオセラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チールー ピュージェット サウンド バイオセラピューティクス コーポレイション filed Critical チールー ピュージェット サウンド バイオセラピューティクス コーポレイション
Publication of JP2019520063A publication Critical patent/JP2019520063A/ja
Publication of JP2019520063A5 publication Critical patent/JP2019520063A5/ja
Priority to JP2021184049A priority Critical patent/JP2022010244A/ja
Application granted granted Critical
Publication of JP7301540B2 publication Critical patent/JP7301540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018562201A 2016-05-26 2017-05-02 抗体の混合物 Active JP7301540B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021184049A JP2022010244A (ja) 2016-05-26 2021-11-11 抗体の混合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342167P 2016-05-26 2016-05-26
US62/342,167 2016-05-26
PCT/US2017/030676 WO2017205014A1 (en) 2016-05-26 2017-05-02 Mixtures of antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021184049A Division JP2022010244A (ja) 2016-05-26 2021-11-11 抗体の混合物

Publications (3)

Publication Number Publication Date
JP2019520063A JP2019520063A (ja) 2019-07-18
JP2019520063A5 JP2019520063A5 (https=) 2020-06-18
JP7301540B2 true JP7301540B2 (ja) 2023-07-03

Family

ID=58709577

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562201A Active JP7301540B2 (ja) 2016-05-26 2017-05-02 抗体の混合物
JP2021184049A Withdrawn JP2022010244A (ja) 2016-05-26 2021-11-11 抗体の混合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021184049A Withdrawn JP2022010244A (ja) 2016-05-26 2021-11-11 抗体の混合物

Country Status (7)

Country Link
US (2) US11130808B2 (https=)
EP (1) EP3463451A1 (https=)
JP (2) JP7301540B2 (https=)
CN (1) CN109475627B (https=)
AU (1) AU2017269115B2 (https=)
CA (1) CA3025162A1 (https=)
WO (1) WO2017205014A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
CN109134658B (zh) 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
TW201834688A (zh) * 2017-02-24 2018-10-01 日商中外製藥股份有限公司 藥學組成物、抗原結合分子、治療方法以及篩選方法
ES2863412T3 (es) 2017-03-29 2021-10-11 Shionogi & Co Composición farmacéutica para el tratamiento del cáncer
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
JP2019151621A (ja) * 2018-02-28 2019-09-12 学校法人藤田学園 Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2020180811A1 (en) 2019-03-04 2020-09-10 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
WO2021041678A1 (en) 2019-08-30 2021-03-04 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
CN120383671A (zh) * 2019-09-30 2025-07-29 阿迪马布有限责任公司 被工程化用于优先轻链配对的ch1结构域变体和包括所述ch1结构域变体的多特异性抗体
CA3160436A1 (en) * 2019-12-17 2021-06-24 Jack Chongyang LI Bispecific antibodies with alternatively matched interchain cysteines and uses thereof
EP4093875A4 (en) * 2020-01-20 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Ligand-binding fusion proteins
WO2022023559A1 (en) * 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
US20230322955A1 (en) * 2020-08-20 2023-10-12 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
EP4186926A4 (en) * 2020-08-28 2024-06-05 Harbour Biomed US, Inc. ANTI-CCR8 ANTIBODIES AND CORRESPONDING APPLICATION
CN114437226A (zh) * 2020-11-05 2022-05-06 杭州菁因康生物科技有限公司 制备双特异性抗体的方法
WO2022178319A1 (en) * 2021-02-18 2022-08-25 Qilu Puget Sound Biotherapeutics Corporation Combinations of anti-pd1 and anti-ctla4 antibodies
CN112961245B (zh) * 2021-02-24 2023-07-25 重庆精准生物技术有限公司 一种靶向cd96的双特异性抗体及其制备方法和用途
MX2023012324A (es) * 2021-04-20 2023-10-30 Amgen Inc Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
CA3217487A1 (en) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Heterodimeric antibodies and antigen-binding fragment thereof
EP4370545A1 (en) * 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
US12240910B2 (en) 2021-07-14 2025-03-04 Genentech, Inc. Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use
CN117957258A (zh) * 2021-07-19 2024-04-30 中外制药株式会社 利用融合多肽的蛋白酶介导的靶向特异性细胞因子递送
US12441816B2 (en) * 2021-09-21 2025-10-14 Qilu Puget Sound Biotherapeutics Corporation Heterodimeric Fc for making fusion proteins and bispecific antibodies
CN118660720A (zh) * 2022-02-22 2024-09-17 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
TW202346594A (zh) * 2022-03-11 2023-12-01 中國大陸商科望（上海）生物醫藥科技有限公司 經修飾之抗體及其用途
WO2023198089A1 (zh) * 2022-04-13 2023-10-19 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
US20250376525A1 (en) * 2022-06-28 2025-12-11 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof
EP4548930A4 (en) * 2022-06-30 2025-10-22 Qilu Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING A MIXTURE OF ANTI-CTLA4 AND ANTI-PD1 ANTIBODIES AND ITS THERAPEUTIC USE
JP2025524024A (ja) 2022-07-22 2025-07-25 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 多重特異性抗体の重鎖及び軽鎖の相同対合を促進する変異体
JPWO2024143442A1 (https=) 2022-12-27 2024-07-04
EP4655595A1 (en) * 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
AU2024341660A1 (en) * 2023-09-11 2026-03-12 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025117485A1 (en) * 2023-11-29 2025-06-05 Qilu Puget Sound Biotherapeutics Corporation Anti-il33 and anti-tslp antibodies, and mixtures
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510084A (ja) 2011-03-17 2014-04-24 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法
JP2015502409A (ja) 2011-12-20 2015-01-22 メディミューン，エルエルシー 二重特異的抗体足場用改変ポリペプチド
JP2015515275A (ja) 2012-04-20 2015-05-28 メルス・ベー・フェー Ｉｇ様分子の生産方法および生産手段
JP2015522295A (ja) 2012-07-25 2015-08-06 スーチョウ アルファマブ カンパニー リミテッド 電荷の斥力相互作用を使用することによりホモダイマータンパク質の混合物を調製するための方法
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
SI1583830T1 (sl) * 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
CN104262483A (zh) 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
WO2012125495A2 (en) 2011-03-11 2012-09-20 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
CN110669136A (zh) * 2012-11-05 2020-01-10 全药工业株式会社 抗体或抗体组合物的制备方法
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6385357B2 (ja) 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
US10118971B2 (en) 2013-03-13 2018-11-06 Ibentrus, Inc. Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
CA2919076C (en) 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
EP3080158A4 (en) 2013-12-09 2018-03-21 Adimab, LLC Polyclonal mixtures of antibodies, and methods of making and using them
JP2019534044A (ja) * 2016-11-08 2019-11-28 クイル ピュージェット サウンド バイオセラピューティクス コーポレーション 抗ｐｄ１および抗ｃｔｌａ４抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510084A (ja) 2011-03-17 2014-04-24 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法
JP2015502409A (ja) 2011-12-20 2015-01-22 メディミューン，エルエルシー 二重特異的抗体足場用改変ポリペプチド
JP2015515275A (ja) 2012-04-20 2015-05-28 メルス・ベー・フェー Ｉｇ様分子の生産方法および生産手段
JP2015522295A (ja) 2012-07-25 2015-08-06 スーチョウ アルファマブ カンパニー リミテッド 電荷の斥力相互作用を使用することによりホモダイマータンパク質の混合物を調製するための方法
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE REVIEWS CLINICAL ONCOLOGY，2016年05月04日，Vol.13, No.8，P.473-486

Also Published As

Publication number Publication date
JP2022010244A (ja) 2022-01-14
CA3025162A1 (en) 2017-11-30
AU2017269115A1 (en) 2018-11-29
US20190248899A1 (en) 2019-08-15
EP3463451A1 (en) 2019-04-10
AU2017269115B2 (en) 2024-06-20
CN109475627A (zh) 2019-03-15
CN109475627B (zh) 2023-01-06
US20220073615A1 (en) 2022-03-10
US11130808B2 (en) 2021-09-28
WO2017205014A1 (en) 2017-11-30
JP2019520063A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
JP7301540B2 (ja) 抗体の混合物
AU2025283517A1 (en) Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
TWI837084B (zh) 促凝血抗體
AU2013351888C1 (en) Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2729496B1 (en) Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
EP3878964A1 (en) Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
CN114901311A (zh) Tnf样配体1a（tl1a）的人源化抗体及其用途
CN114349866B (zh) 一种PD-1/TGF-beta四价双特异性抗体、其制备方法和用途
CN112513096B (zh) 改进的促凝血抗体
JP2023512089A (ja) 二重特異性第ｖｉｉｉ因子模倣抗体
JP2025083342A (ja) ＴＧＦ－βＲＩＩ結合タンパク質
JP2025524347A (ja) ガンマデルタｔ細胞受容体に結合するバリアント抗体
IL293310A (en) Bispecific anti-ccl2 antibodies
TW202307004A (zh) 抗ｃｅａ抗體及使用方法
CN121079328A (zh) 抗alk-1抗体及其用途
US12441816B2 (en) Heterodimeric Fc for making fusion proteins and bispecific antibodies
US20250282892A1 (en) Bispecific antibodies binding to her-3 and to either her-2 or egfr
US20220127361A1 (en) TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/TGF-beta, PREPARATION METHOD THEREFOR, AND USE THEREOF
JP2026514143A (ja) Ｏｘ４０ｌに結合する抗体及びその使用方法
WO2025027511A1 (en) Molecules that bind to mutant calreticulin and uses thereof
HK40071803A (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230621

R150 Certificate of patent or registration of utility model

Ref document number: 7301540

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150